Atopic Dermatitis

Turn Therapeutics initiates a groundbreaking clinical trial for GX-03, the first topical IL-36 inhibitor targeting moderate to severe eczema.

An expert discusses how successful atopic dermatitis management requires patient-centered care and shared decision-making, emphasizing that treatment selection should match disease impact rather than just body surface area, with both biologics and JAK inhibitors offering safe and effective options.

An expert discusses how patient preferences, particularly needle anxiety, must be balanced with treatment effectiveness, demonstrating that oral JAK inhibitors can be excellent alternatives for patients who cannot tolerate injectable biologics.

Christopher Bunick, MD, PhD, highlights how dupilumab transforms atopic dermatitis treatment in children, improving health outcomes and quality of life beyond skin symptoms.

A recent study reveals a significant link between alopecia areata severity and increased risk of atopic dermatitis, especially in adolescents.

LEO Pharma reveals promising interim results for tralokinumab in treating moderate to severe atopic dermatitis on hands, enhancing patient quality of life.

Achieving optimal treatment targets and minimal disease activity significantly enhances health-related quality of life and satisfaction in patients with atopic dermatitis.

New 16-week data from the phase 2 APEX clinical trial demonstrated the anti-IL-13 antibody's efficacy across all key endpoints.

Explore the potential of whole-body cryotherapy as a novel, nonpharmacologic treatment for effectively managing atopic dermatitis symptoms.

An expert discusses how a 55-year-old African American man’s case highlights challenges in diagnosing atopic dermatitis in skin of color, emphasizing the importance of recognizing different disease presentations and addressing postinflammatory hyperpigmentation concerns.

An expert discusses how a 5-year-old child with severe atopic dermatitis affecting sleep and school performance demonstrates the need for systemic therapy escalation, with dupilumab being an ideal choice given its efficacy for both atopic dermatitis and comorbid asthma.

Delgocitinib ointment shows promise as an effective, well-tolerated treatment for atopic dermatitis on the face and neck, enhancing patient satisfaction and reducing adverse effects.

A new paper highlights Alphyn Biologics' Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications.

Anabela Cardoso, MD, reflects on specific data from the phase 3b ADmirable trial evaluating the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

Nearly all injection site reactions among patients in the ARCADIA 1/2 and OLYMPIA 1/2 clinical trials were mild and transient in nature.

Nektar Therapeutics reveals positive results from the REZOLVE-AD study, showcasing rezpegaldesleukin's efficacy in treating moderate to severe AD.

Arcutis Biotherapeutics' roflumilast cream 0.15% gains strong AAD endorsement for effective AD management in adults and children.

An expert discusses how personalizing systemic atopic dermatitis treatment requires considering factors such as disease severity, patient impact, treatment failures, age, comorbidities, and patient preferences when selecting between biologics and JAK inhibitors.

An expert discusses how atopic dermatitis creates significant physical and quality-of-life burdens affecting up to 20% of pediatric and 10% of adult patients globally, with presentations varying across age groups and key unmet needs including improved access to care and disease recognition across different skin tones.

The new PDUFA date is set for September 2025.

Anabela Cardoso, MD, shares data from the phase 3b ADmirable trial—the first study to evaluate the safety and efficacy of lebrikizumab in patients with moderate to severe AD and pigmented skin.

A real-world study shows the effectiveness of upadacitinib and abrocitinib for moderate to severe atopic dermatitis after 52 weeks of treatment.

Pediatric dermatologist Mercedes E. Gonzalez, MD, discusses roflumilast's promise as a safe, nonsteroidal treatment for atopic dermatitis in infants.

Catch up on all updates and advancements shared at this year's Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.